Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction Models for Sentinel Lymph Node Metastasis in Clinically Node-Negative Breast Cancer: Validation of Existing Nomograms, Model Development, and Ensemble Evaluation.

World journal of surgery·2026

Same author

From legalisation to practice: implementation of newly legalised health interventions in healthcare settings - a systematic review.

BMJ open·2026

Same author

Cost Analysis Just One Aspect of Deciding Between Disposable and Reusable Instruments.

ANZ journal of surgery·2026

Same author

Public support for mitochondrial donation: an Australian knowledge and attitudes study.

Reproductive biomedicine online·2026

Same author

Site-specific porous hydrogel coating and characterization for tunable drug- eluting ureteral stent.

International journal of pharmaceutics·2026

Same author

Mathematical Prediction Models for Sentinel Node Status in Early-Stage Breast Cancer: Protocol for a Systematic Review.

JMIR research protocols·2026

Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018

Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018

Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018

Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018

Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018

Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate specific antigen - useful screening tool or potential liability?

Patrick Mahar¹, Shomik Sengupta, Karinne Ludlow

¹Urology Unit, The Alfred, Melbourne, Victoria. p.mahar@alfred.org.au

Australian Family Physician

|September 30, 2010

Summary

This summary is machine-generated.

Prostate specific antigen (PSA) screening for prostate cancer is not widely endorsed in Australia, except for specific age groups. General practitioners face legal considerations when deciding on PSA testing due to conflicting guidelines.

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 8, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

Urology
Oncology
General Practice

Background:

Uncertainty persists regarding prostate specific antigen (PSA) screening for prostate cancer.
Recent randomized controlled trials and authoritative body statements have not resolved this uncertainty.

Purpose of the Study:

Summarize Australian authoritative position statements on PSA screening.
Describe legal considerations for general practitioners (GPs) regarding PSA testing.

Main Methods:

Review of authoritative position statements from Australian representative bodies.
Analysis of legal provisions concerning peer professional opinion in Australia.

Main Results:

Most Australian authoritative bodies do not endorse PSA as a primary screening tool.
An exception exists for men aged 55-69 in certain circumstances.
GPs have legal justification for ordering or not ordering PSA tests for asymptomatic patients.

Conclusions:

PSA is generally not recommended as a primary screening tool by Australian authorities.
Decision-making for PSA testing involves navigating conflicting guidelines and legal considerations.
Referral to specialists is appropriate when uncertainty remains regarding PSA screening.